Keybank National Association OH decreased its stake in shares of Haemonetics Corporation (NYSE:HAE) by 4.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,200 shares of the medical instruments supplier’s stock after selling 1,775 shares during the quarter. Keybank National Association OH owned about 0.07% of Haemonetics Corporation worth $1,669,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Arizona State Retirement System increased its stake in Haemonetics Corporation by 1.1% during the 2nd quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 300 shares in the last quarter. Aperio Group LLC increased its stake in Haemonetics Corporation by 15.0% during the 2nd quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 1,393 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Haemonetics Corporation by 12.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock valued at $928,000 after purchasing an additional 2,553 shares in the last quarter. Kirr Marbach & Co. LLC IN increased its stake in Haemonetics Corporation by 56.3% during the 2nd quarter. Kirr Marbach & Co. LLC IN now owns 11,300 shares of the medical instruments supplier’s stock valued at $446,000 after purchasing an additional 4,070 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in Haemonetics Corporation by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after purchasing an additional 200 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Haemonetics Corporation (HAE) Holdings Cut by Keybank National Association OH” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://theolympiareport.com/2017/11/12/haemonetics-corporation-hae-holdings-cut-by-keybank-national-association-oh.html.

Shares of Haemonetics Corporation (NYSE:HAE) opened at $54.52 on Friday. The firm has a market cap of $2,879.64, a price-to-earnings ratio of 33.45, a PEG ratio of 4.08 and a beta of 0.91. Haemonetics Corporation has a 52 week low of $36.44 and a 52 week high of $55.10. The company has a quick ratio of 1.72, a current ratio of 2.17 and a debt-to-equity ratio of 0.22.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.07. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $219.12 million. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.38 earnings per share. research analysts forecast that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.

HAE has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Jefferies Group LLC restated a “buy” rating and set a $48.00 price target on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Wednesday, August 9th. Morgan Stanley restated an “equal weight” rating and set a $43.00 price target (up previously from $38.00) on shares of Haemonetics Corporation in a research note on Friday, October 6th. Finally, Craig Hallum reiterated a “hold” rating and issued a $50.00 price objective (up previously from $40.00) on shares of Haemonetics Corporation in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Haemonetics Corporation currently has an average rating of “Hold” and an average price target of $51.33.

Haemonetics Corporation Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.